Trinity Bivalacqua
Director, Urologic Oncology · Perelman School of Medicine at the University of Pennsylvania
Credentials: · · · · ·
History
- 2014–2017
- 2000–2004
Research
Neurohumoral features of myocardial stunning due to sudden emotional stress
New England Journal of Medicine · 2005 · 2,368 citations
The Lancet Oncology · 2021 · 402 citations
Proceedings of the National Academy of Sciences of the United States of America · 2004 · First of 10 authors · 273 citations
89 papers · 56 as a resident
- HC
82 papers · 48 as a resident
72 papers
61 papers
50 papers
48 papers · 12 as a resident
- NS
44 papers · 37 as a resident
43 papers
Grants
- 2011–2017
Roles of RhoA/Rho-Kinase Signaling in Cavernous Neurons Following Axonal Injury
National Institute of Diabetes and Digestive and Kidney Diseases · K08
Contact PI · $793.5K · Johns Hopkins University
- 2014–2016
TNF-Alpha Activation of Rho-Kinase in Cavernous Nerve Injury
National Institute of Diabetes and Digestive and Kidney Diseases · R03
Contact PI · $162K · Johns Hopkins University
Clinical trials
- 2013
Improving Sensitivity of Urine Cytology for Bladder Cancer
Principal investigator · Withdrawn
Johns Hopkins University
- 2010–2014
Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit
Principal investigator · Completed · Phase 1
Tengion
- 2026–2029
Site PI · Not yet recruiting · Phase 1
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
- 2024–2027
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Site PI · Recruiting · Phase 2
CG Oncology, Inc.